| DC20271 |
LUT014
Featured
|
LUT014 is a novel BRAF agonist. |
|
| DC12117 |
Luteolin 7-O-glucuronide (Luteolin 7-glucuronide4)
Featured
|
Luteolin 7-O-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC50s of 17.63, 7.99, 11.42, 12.85, 0.03 μM for MMP-1, MMP-3, MMP-8, MMP-9, MMP-13, respectively. |
|
| DC12118 |
Luteolin-3-O-beta-D-glucuronide |
Luteolin-3-O-beta-D-glucuronide is a luteolin glucosiduronic acid consisting of luteolin having a beta-D-glucosiduronic acid residue attached at the 3'-position. |
|
| DC12120 |
Luteolin-7-rutinoside |
Luteolin-7-rutinoside has both anti-arthritic and antifungal activities, can result in a combination therapy for the treatment of fungal arthritis due to C. albicans infection. |
|
| DC11172 |
LV-320 |
LV-320 (LV320) is a novel potent, cell-active, allosteric inhibitor of the autophagy-related cysteine protease ATG4B with IC50 of 24.5 uM in ATG4B cleavage assays. |
|
| DC23133 |
LX-1031 |
LX-1031 is a potent, orally active tryptophan 5-hydroxylase (TPH) inhibitor with potency of 10-100 nM, reduces 5-HT synthesis peripherally. |
|
| DC7456 |
LX1606 Hippurate
Featured
|
LX1606 is an orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor with potential antiserotonergic activity. |
|
| DC10754 |
LX2343
Featured
|
LX-2343 is a novel non-ATP competitive PI3K inhibitor, negatively regulating AKT/mTOR signaling, thus promoting autophagy, and increasing A-beta clearance. |
|
| DC10765 |
LX-2761 |
LX2761 is a locally acting SGLT1 inhibitor that is highly potent in vitro and delays intestinal glucose absorption in vivo to improve glycemic control. |
|
| DC21251 |
LX-2931 |
LX-2931 (LX2931) is a potent, selective and orally bioavailable S1P lyase (S1PL) inhibitor. |
|
| DC7921 |
Sotagliflozin (LX-4211)
Featured
|
LX-4211 is a potent dual SGLT2/1 inhibitor; Antidiabetic agents. |
|
| DC23136 |
LX7101 |
LX7101 is a potent, dual LIMK and ROCK inhibitor with IC50 of 4.3/32//69/32/ nM for LIMK2/LIMK1/ROCK1/ROCK2, respectively. |
|
| DC10828 |
LXH254
Featured
|
LXH254 is a potent CRAF inhibitor extracted from patent WO2018051306A1, Compound A. LXH254 also is a potent BRAF inhibitor. |
|
| DC2072 |
LXR623
Featured
|
LXR-623 is a novel Liver X Receptor modulator |
|
| DC26012 |
LXS-196
Featured
|
LXS196 is a potent, selective and orally active protein kinase C (PKC) inhibitor, with IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively. It can be used for the treatment of uveal melanoma. |
|
| DC21256 |
LY 2318912 |
LY 2318912 is a potent, competitive, small molecule inhibitor of anandamide uptake with IC50 of 7.27 nM, shows high affinity against anandamide transporter binding site with Kd o f7.62 nM. |
|
| DC8602 |
LY311727
Featured
|
LY 311727 is a specific group II sPLA2 (phospholipase A2 (PLA2)) inhibitor which has been reported to attenuate VEGF-mediated platelet-activating factor (PAF) synthesis in HUVEC and BAEC cells. |
|
| DC23633 |
LY 392098 |
LY 392098 is a selective, potent and centrally active positive allosteric modulator of AMPAR. |
|
| DC7944 |
LY2090314
Featured
|
LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50s of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β respectively. |
|
| DC7189 |
LY-2109761 |
LY2109761 is a novel selective TGF-β receptor type I/II (TβRI/II) dual inhibitor with Ki of 38 nM and 300 nM, respectively; shown to negatively affect the phosphorylation of Smad2. |
|
| DC8435 |
LY2119620
Featured
|
LY2119620 is a specific, and allosteric agonist of human M2 and M4 muscarinic acetylcholine receptors. |
|
| DC6306 |
LY2157299(Galunisertib)
Featured
|
LY2157299 is a potent TGFβ receptor I (TβRI) inhibitor with IC50 of 56 nM. Phase 2. |
|
| DC2045 |
LY2183240 |
LY2183240 is a novel and highly potent blocker of anandamide uptake (IC50 = 270 pM). |
|
| DC8630 |
Ralimetinib 2MsOH(LY2228820)
Featured
|
LY2228820 is a novel and potent p38MAPK inhibitor (the IC50 for p38αMAPK and p38βMAPK were 7 nM and 3 nM, respectively). |
|
| DC12130 |
LY223982 |
LY223982 is a potent and specific inhibitor of leukotriene B4 receptor, with an IC50 of 13.2 nM against [3H]LTB4 binding to LTB4 receptor. |
|
| DC9304 |
LY2334737
Featured
|
LY2334737 is an orally available prodrug of gemcitabine which is a nucleoside analog used as chemotherapy. |
|
| DC9975 |
Ly 2365109 Hydrochloride;n-[2-[4-(1,3-benzodioxol-5-yl)-2-(1,1-dimethylethyl)phenoxy]ethyl]-n-methylglycinehydrochloride
Featured
|
LY2365109 is a potent and selective GlyT1 inhibitors with IC50 value of 15.8 nM. |
|
| DC8065 |
LY2409881 trihydrochloride
Featured
|
LY2409881 is a novel inhibitor of IκB kinase β (IKK2). |
|
| DC23720 |
LY2452473
Featured
|
LY2452473 is an orally bioavailable, selective androgen receptor modulator (SARM). |
|
| DC10782 |
LY2510924
Featured
|
LY2510924 is an inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. |
|
